Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT05990998
Overview
Both fibroblast activation protein (FAP)-targeted imaging and somatostatin receptors (SSTR)-targeted imaging were the promising imaging modalities for the diagnosis of primary and metastatic nasopharyngeal carcinoma (NPC). This prospective study is going to investigate to compare the diagnostic efficacy of 68Ga-FAPI and 68Ga-DOTATATE in detecting primary and metastatic NPC lesions, thereby obtaining a more accurate examination method of NPC.
Sponsor
First Affiliated Hospital of Fujian Medical University
Phase
Phase 1/2
Contacts
Weibing Miao, MD
miaoweibing@126.com
86-0591-87981618
jieling zheng
775304265@qq.com
86-599-87981619
ClinicalTrials.gov
NCT05990998Drug / Compound
Help us improve your experience